|
|
|
|
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized,
Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of
Advanced Metastatic Colon Cancer ... More
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of
KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium ... More
Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of
Advanced Metastatic Colon Cancer ... More
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of
KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium ... More
Keryx maintains this website as a service to the Internet community. Access to and use of information presented on the Keryx website is subject to the terms and conditions described in "Use of the Keryx website".
Copyright © 2009 by Keryx Biopharmaceuticals, Inc.
Copyright © 2009 by Keryx Biopharmaceuticals, Inc.